ARPA-H Commits $144 Million to the First Clinical Trials Designed to Extend Healthspan

On February 24, 2026, the Advanced Research Projects Agency for Health (ARPA-H) announced the seven research teams funded through its PROactive Solutions for Prolonging Resilience (PROSPR) program. The investment: up to $144 million over five years. The goal: develop tools and therapies that extend healthspan by detecting and intervening on the earliest changes associated with aging.

This isn’t a grant announcement. It’s a signal that the U.S. federal government now considers healthspan extension a legitimate biomedical priority — with the budget to prove it.

Why PROSPR Matters

The fundamental problem with developing anti-aging therapeutics has always been time. Clinical trials require measurable endpoints, and the endpoint of “aging” — disease, disability, death — takes decades to manifest. No pharmaceutical company can run a 30-year trial waiting for outcomes.

PROSPR solves this by investing in surrogate biomarkers: molecular and physiological markers that change early in the aging process and predict long-term health outcomes. If validated, these biomarkers would allow clinical trials to measure drug efficacy in one to three years instead of decades. That’s not incremental progress — it’s a structural change in how aging research gets done.

As ARPA-H Director Alicia Jackson put it: “PROSPR represents a tectonic shift in how we study healthy aging.”

The Seven Teams and What They’ll Do

The PROSPR program spans institutions across the United States, each tackling a different piece of the puzzle:

• Stanford University will harmonize existing large-scale health datasets to generate a “healthspan score” (PROSPR-IC score) and test its accuracy in a one-year lifestyle intervention, supported by in-home digital health assessment technology.

• UT Health San Antonio will establish a regulatory pathway for testing aging therapeutics by conducting a phase 3 hybrid trial repurposing three FDA-approved drugs: an SGLT2 inhibitor, rapamycin, and semaglutide — three compounds that longevity clinics have already been prescribing off-label for years.

• Columbia University will identify biomarkers responsive to interventions that improve aging trajectories, aiming to create validated surrogate endpoints for future trials.

• University of Rochester leads a multi-institutional consortium (Brown, UConn, UTMB, UTHealth Houston, University of Nebraska, and Transposon Therapeutics) focused on defining the earliest physiological and biochemical changes that predict long-term outcomes.

Additional teams will pioneer decentralized, in-home trial designs — removing the requirement for patients to visit research centers repeatedly, which has historically limited enrollment in aging studies.

What This Means for Longevity Clinics

The implications for the clinical longevity sector are substantial.

Validation of the off-label playbook. The UT San Antonio trial is explicitly testing rapamycin, semaglutide, and SGLT2 inhibitors — three drugs that have become staples of longevity clinic protocols despite the absence of FDA-approved aging indications. If PROSPR generates positive data, it would provide the evidentiary foundation that critics have demanded and that clinics have lacked. If the data is negative or mixed, it would force a reckoning.

Standardized biomarker panels. One of the biggest problems in longevity medicine today is that every clinic measures different things, in different ways, with different reference ranges. PROSPR’s biomarker validation work could establish a common language — a set of agreed-upon markers that define aging trajectories and treatment response. For consumers comparing clinics, this would be transformative.

A regulatory pathway for “healthspan.” Perhaps most importantly, PROSPR is explicitly building the infrastructure for the FDA to evaluate aging-related therapies. Today, the FDA does not recognize “aging” as a disease or “healthspan extension” as an approvable indication. PROSPR aims to change that by creating validated surrogate endpoints that regulators can accept. If successful, this opens the door to a new category of FDA-approved healthspan therapeutics.

The Scale of the Commitment

The $144 million PROSPR allocation is part of a broader pattern. According to market tracking by New Market Pitch, the U.S. government has committed over $166 million to longevity research through ARPA-H alone, with two separate awards in February 2026 (the PROSPR program and a $22 million contract to Linnaeus Therapeutics for its LNS8801 healthspan preservation drug).

This places the federal government alongside venture capital as a significant source of funding for the longevity sector — a development that was difficult to imagine even two years ago.

The Bridge Between Research and Clinics

PROSPR doesn’t directly fund longevity clinics. But it addresses the single biggest gap the sector faces: the absence of rigorous, validated evidence that aging interventions work in humans.

If PROSPR succeeds in establishing surrogate biomarkers and demonstrating drug efficacy in short-duration trials, the longevity clinic model shifts from experimental to evidence-based. Insurance coverage, regulatory approval, and institutional adoption all become possible conversations rather than aspirational ones.

The program’s goal, as stated by ARPA-H, is to enable a new “healthspan industry.” For an agency that helped create the internet (through DARPA) and mRNA vaccines (through BARDA), that ambition deserves attention.